Proof-of-concept Study Shows DCCR Treatment Addresses Unmet Needs in PWS
Results of a Phase 2 clinical trial testing diazoxide chloride controlled release (DCCR) in people with Prader-Willi syndrome (PWS) showed the investigational therapy can address some unmet needs in this patient population — namely hyperphagia, or excessive appetite, and aggressive behavior. The data were published in the journal …